ABSTRACT Background: Animal studies suggest that dietary cis-9,trans-11 (c9,t11) conjugated linoleic acid (CLA) may inhibit or regress the development of atherosclerosis. The effect of CLA on atherosclerosis has not been assessed in humans. Objective: We investigated the effect of c9,t11 CLA supplementation on aortic pulse wave velocity (a marker of atherosclerosis) and on cardiovascular risk factors in overweight and obese but otherwise apparently healthy subjects. Design: In a double-blind, randomized, placebo-controlled, parallelgroup trial, we randomly assigned 401 subjects, aged 40-70 y and with a body mass index (in kg/m 2 ) 25, to receive either 4 g CLA/d (2.5 g c9,t11 CLA/d and 0.6 g trans-10,cis-12 CLA/d) or placebo supplements for 6 mo. Aortic pulse wave velocity, blood pressure, anthropometric characteristics, and concentrations of fasting lipid, glucose, insulin, and C-reactive protein were measured before and after supplementation. Results: During the intervention, mean (6SE) pulse wave velocity did not change in the c9,t11 CLA group (D0.00 6 0.07) compared with the placebo group (D0.09 6 0.06). There was no effect of c9,t11 CLA supplementation on blood pressure, body composition, insulin resistance, or concentrations of lipid, glucose, and C-reactive protein.
INTRODUCTION
Conjugated linoleic acids (CLAs) are positional and geometric isomers of linoleic acid, in which the 2 double bounds are conjugated (1) . CLA is a fatty acid produced in the rumen of ruminants and that occurs naturally in the lipid fraction of ruminant meat and milk. The cis-9,trans-11 (c9,t11) CLA isomer accounts for '90% of CLA isomers in ruminant fat (2) . CLA may have antiatherogenic effects, possibly by acting as an agonist of peroxisome proliferator-activated receptors or as a cyclooxygenase inhibitor, thereby modifying hepatic lipid metabolism and inflammatory activity (3) . However, exact mechanisms are unclear.
Whereas industrial trans fatty acid consumption has been related to increased risk of cardiovascular disease (CVD), observational studies reported no such associations for ruminant trans fatty acids, such as vaccenic acid and CLA (4) . However, this may also be attributed to its low dietary consumption. Indeed, 2 controlled-feeding trials, which included 38-40 participants, showed a deterioration in blood lipids with daily ruminant trans fatty acid intakes of 3.6-5.0% of energy (5, 6) but not at 1.5% of energy intake (6) .
Animal studies that investigated CLA mixtures [comprising equal proportions of c9,t11 and trans-10,cis-12 (t10,c12) CLA] at 0.1-5.0% of total dietary intake, consistently related CLA to inhibited atherogenesis (7) and some, but not all, reported improvements in CVD risk markers, such as blood lipids (8) . However, divergent effects of the c9,t11 and t10,c12 isomers have been reported, and c9,t11 CLA (at 1.0-2.1%) is the active isomer in the inhibition of atherogenesis and improvement in blood lipid and glucose profiles (9, 10) .
In humans the c9,t11 isomer in general seems to have no significant effect on CVD risk markers, such as blood lipids (11) (12) (13) (14) (15) (16) , inflammatory markers (12) (13) (14) (16) (17) (18) , and adhesion molecules (14, 16, 17, 19) . One study reported decreased insulin sensitivity (13) , whereas others did not (12, 15, 16, 20) . However, because of variations in study design, such as supplementation doses (which varied from 0.6 to 5.5 g/d), the effects of supplementation with a relatively low c9,t11 CLA dose on CVD risk markers are still unclear.
Human studies on atherogenesis are scarce (21, 22) . One study observed a deterioration of endothelial function, a marker of vascular function, with a mixture of 4.5 g CLA/d (22) , but this was not confirmed elsewhere (21) . As far as we are aware, no human studies have addressed the effects of CLA, or the c9,t11 isomer, on aortic pulse wave velocity (PWV), which is a measure of aortic stiffness and may be regarded as an early marker of atherosclerosis. Because endothelial dysfunction relates to increased arterial stiffness (23) , studies into PWV may add valuable insights into a potential antiatherogenic mechanism of c9,t11 CLA in humans. Therefore, we investigated the effect of 6 mo of supplementation with c9,t11 CLA on aortic PWV. We also studied the effects of c9,t11 CLA on blood pressure, blood lipids, insulin resistance, body composition, and C-reactive protein (CRP) in 346 overweight and obese adults.
SUBJECTS AND METHODS
We conducted a single-center, double-blind, randomized, placebo-controlled, parallel-group trial that compared the effects of c9,t11 CLA supplementation with placebo supplements for 6 mo, on 1) changes in aortic PWV and 2) changes in insulin resistance, blood pressure, anthropometric characteristics, and concentrations of blood lipids, glucose, insulin, and CRP. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonization of Good Clinical Practice guidelines, and appropriate regulatory requirements. The study protocol was approved by the Institutional Review Board of the University Medical Center Utrecht in Utrecht, Netherlands. All participants provided written informed consent.
Subjects
A total of 1048 potential participants were recruited through the Julius Center "POKA" database (comprising subjects interested in participating in studies) and through a random selection from the municipal registers of a large and middle-large town in the middle part of the Netherlands (Figure 1 ). Subjects were invited to take part in the study by mail and could reply by a response-card. Interested subjects were contacted by telephone to explain the study aims. Leaflets were mailed with further study information and criteria for eligibility. After 1 wk, these subjects were contacted again and invited to the information and screening/randomization visit. In total, 501 potential participants were screened, of whom 100 were excluded after eligibility criteria were checked, which left 401 subjects to be randomly assigned to study groups ( Figure 1) . Inclusion criteria at screening were apparently healthy men and women, aged 40-70 y, with a body mass index (BMI; in kg/m 2 ) of 25. The main exclusion criteria at screening were as follows: a systolic blood pressure of 160 mm Hg or a diastolic blood pressure of 90 mm Hg, or current use of blood pressure-lowering drugs; a total cholesterol concentration of 8 mmol/L or current use of lipidlowering drugs; or inability to perform PWV measurements ( Figure 1 ).
Intervention, compliance, and safety
Eligible participants were randomly assigned through a webbased application to receive either c9,t11 CLA or placebo in a 1:1 ratio with the use of a minimalization procedure. Randomization was stratified for sex. Both c9,t11 CLA and placebo supplements were provided in the form of soft gel capsules. The c9,t11 CLA oil was manufactured from safflower oil. Four capsules of 1 g oil each were taken daily. The choice of this dose was not straightforward because extrapolation from animal trials is difficult and no human trials on PWV had been done. We expected to have an effect with a dose of 4 g/d, because this is known to affect other systems in the body, such as fat distribution (8) . A lower dose may have had no effect and a higher dose may have decreased compliance. CLA capsules provided 80% CLA isomers, of which 80% (2.5 g/d) was c9,t11 CLA and 20% (0.6 g/d) was t10,c12 CLA. The percentage of energy provided by c9,t11 CLA and t10,c12 CLA during the intervention was '1% and '0.3%, respectively (based on a daily intake of 2000-2500 kcal). Because c9,t11 CLA is the abundant isomer in the product, we refer to the product as c9,t11 CLA. The placebo capsules contained an equal amount of fat and were composed of a blend of palm oil (80%) and soybean oil (20%), which resembles the average fatty acid composition of the fat consumed by a Western population ( Table 1) . Capsules were produced and provided by Lipid Nutrition, Wormerveer, Netherlands.
Blinded study capsules were supplied in individual, preprepared, numbered bottles. Subjects were instructed to return leftover trial capsules to the clinic at each visit (at 3 and 6 mo). The investigators checked compliance but were unaware of treatment allocations for the duration of the study. Compliance was calculated with the following formula: compliance (%) = (number of capsules actually taken since last capsule count/ number of capsules that should have been taken in the same period) · 100.
Self-reported vital signs and adverse events (AEs) were identified at each clinic visit by means of standard questions. Clinically significant abnormal laboratory values, vital signs, and other physical findings were recorded as AEs. Serious adverse events (SAEs) were monitored continuously throughout the entire study period.
PWV measurement
PWV was measured at baseline and after 6 mo (or earlier when subjects dropped out of the study) with the use of the SphygmoCor system (PWV Medical, Sydney, Australia), as described by us previously, with well-trained and certified technicians (24) (25) (26) . Briefly, after the subject rested for 5-10 min in the supine position, PWV was measured by sequential recordings of arterial pressure waveform at the carotid artery and the femoral artery with the use of a hand-held micromanometer-tipped probe on the skin at the site of maximal arterial pulsation. Gating the recordings at those 2 sites to the electrocardiogram allowed PWV to be measured. Recordings were taken when a reproducible signal was obtained with highamplitude excursion (usually 10 consecutive beats) to cover a complete respiratory cycle. The wave transit time was calculated by the system software, with the use of the R wave of a simultaneously recorded electrocardiogram as a reference frame. Distances from the carotid-sampling site to the suprasternal notch and from the suprasternal notch to the femoral artery were measured with a specifically designed compass. The PWV (m/s) was automatically calculated as the distance between the suprasternal notch and the femoral artery minus the distance between the carotid sampling site and the suprasternal notch, divided by the time interval between systolic R wave and femoral systolic up-stroke minus the time interval between systolic R wave and carotid systolic up-stroke. PWV was determined as the mean of 3 consecutive beats recorded during 10 s of data acquisition. All measurements (baseline and end of study) were performed by the same observer. An earlier reproducibility study, performed in 27 participants who underwent 2 PWV measurements within 2 wk (27) , showed a mean (6SD) difference of 0.01 6 1.0 m/s between 2 time points and an intraclass correlation coefficient of 89.6%, which indicates that 89.6% of the variance in the PWV measurements was due to patient differences, whereas 10.4% could be attributed to differences between visits. The CV for PWV was 7.5%.
Measurement of cardiovascular risk factors
At baseline, information on medication use (which included nutritional supplements), medical history (cardiovascular, renal, hepatic, and hematologic diseases), and lifestyle factors (current/ former/nonsmoker and number of cigarettes per day, average number of alcohol units per week) were assessed with the use of a questionnaire. Physical activity scores were calculated with the use of the Modified Baecke Physical Activity Questionnaire, which has been validated in middle-aged and elderly men and women (28, 29) . Both questionnaires were filled out by research nurses during a face-to-face interview with the subjects. Blood pressure was measured by an oscillometric-automated device (DINAMAP 8100; Critikon, Tampa, FL). Measurements were conducted before 1100 after an overnight fast, performed in duplicate with the participant in a sitting position, with 2 min between each measurement. Systolic and diastolic blood pressures were defined as the average of the 2 measurements. Mean arterial pressure was calculated with the use of the following formula: mean arterial pressure = (2 · mean diastolic blood pressure + mean systolic blood pressure)/3. Pulse pressure was defined as systolic blood pressure minus diastolic blood pressure. Central vascular measurements were performed with the use of the SphygomoCor Blood Pressure Analysis System (Sydney, Australia), as described previously (30) . Central aortic pressures were derived by applanation tonometry of the radial artery (31) . The radial pressure waveform was recorded noninvasively with a micromanometer (Millar SPT 301; Millar Instruments, Houston, TX). The probe was held on the skin over the maximal arterial pulsation by hand and pressed down on the artery against the underlying bone. Ascending aortic pressure was derived from the central pressure waveform with the use of a generalized transfer function, which is incorporated into the SphygmoCor device (32) . The European Systematic Coronary Risk Evaluation (SCORE) formula was used to calculate 10-y absolute risk of fatal CVD for each individual (33) . Height and weight were measured once and rounded to the nearest 0.5 cm or 0.5 kg. BMI was calculated as weight in kilograms divided by height in meters squared. Waist circumference was measured at the level of midway between the lower rib and the crista iliaca superior after normal expiration, without pressure of the centimeter at the skin. Hip circumference was measured at the level of the greater trochanter. Both measurements were performed in duplicate and the average taken rounded to the nearest 0.5 cm. Waist-hip ratio was calculated as waist divided by hip circumference in centimeters. After 3 and 6 mo (or earlier when subjects dropped out of the study) mean blood pressure, weight, and waist and hip circumference were measured again. Central vascular measurements, SCORE, and changes in lifestyle (ie, smoking status, physical activity, and alcohol consumption) were recorded at the 6-mo visit.
Biochemical analyses
Plasma concentrations of total and HDL cholesterol, triglycerides, glucose, and insulin were measured in fasting blood samples at baseline and after 6 mo of intervention. Plasma was obtained by centrifugation (3000 · g, 10 min, 4°C) and stored at 280°C until analysis. An automatic enzymatic procedure was used to determine total and HDL cholesterol (DxC800 Beckman; Beckman Coulter, Mijdrecht, Netherlands). Triglycerides were measured with the use of a homogeneous colorimetric technique (DxC800 Beckman; Beckman Coulter). LDL cholesterol concentrations were estimated with the use of the Friedewald formula (34). We were unable to provide reliable estimates of plasma LDL-cholesterol concentrations for 4 subjects because plasma triglyceride concentrations were .4 mmol/L. High-sensitivity CRP concentrations were determined by an immunoturbidimetric assay on the DxC. Glucose concentrations were assessed capillary with the use of a glucose oxidase method (Accu-Check; Roche, Almere, Netherlands).
Insulin was measured with the use of an immunometric technique on an IMMULITE 1000 Analyzer (Siemens Medical Solutions Diagnostics, Los Angeles, CA). The lower limit of detection was 2 mE/L (13.9 pmol/L), and interassay variation was 9% at 6 mE/L (41.7 pmol/L) and ,5.5% at 20-120 mE/L (138.9-833.4 pmol/L) (n = 120). We calculated the homeostasis model assessment of insulin resistance (HOMA-IR) to assess insulin resistance, with the equation HOMA-IR = [fasting insulin (mIU/ L) · fasting glucose (mmol/L)]/22.5 (35) .
Data analysis
Earlier studies reported a change in PWV of between 5% and 10% in a period of 6-12 mo on use of statins (36) (37) (38) (39) . In 60-80-yold men at the Julius Center, we observed a mean (6SD) PWVof 9.0 6 2.5 m/s (26) . Because there were no comparable studies on PWV with food supplements, we used these earlier studies on statins to calculate the power. This calculation, with a 2-sided a of 0.05 and power of 80%, showed that '180 subjects per treatment arm were required to detect an 8.2% difference in change in PWV. The inclusion of a conservatively assumed dropout rate of 15% increased this requirement to '200 subjects per treatment arm.
Continuous baseline characteristics across treatment arms were expressed as mean (6SE) for normally distributed variables and median (range) for non-normally distributed variables. Categoric variables across treatment arms were expressed as n (%). The primary outcome (ie, change in PWV from baseline to 6 mo) was calculated by the subtraction of the 6-mo PWV value from the baseline value. A similar approach was taken for the secondary outcomes. Changes from baseline to 6 mo across treatment arms were expressed as mean (6SE) or n (%) and analyzed in accordance with the intention-to-treat principle. Differences in 6-mo changes between the 2 groups were tested with the use of a 2-sided t test or chi-square test. Within-group changes were tested with a paired t test, Wilcoxon's test, or chi-square test. Because of randomized allocation, no adjustments for baseline levels were made. The analyses were repeated among compliant subjects only and with the use of the per-protocol principle. Furthermore, analyses were repeated with imputed values for missing follow-up PWV values (n = 48) because missing data may not occur at random and may bias the final results (40) . Imputation was performed with the use of linear regression modeling. Statistical analyses were done with the use of SPSS for Windows, version 14.0 (SPSS Inc, Chicago, IL).
RESULTS
In total, 401 subjects were randomly assigned: 200 to the placebo group and 201 to the c9,t11 CLA group. After they were randomly assigned, 7 subjects (4 in the placebo group and 3 in the c9,t11 CLA group) were excluded because they met the exclusion criteria and should therefore not have been assigned to a group. After 6 mo of follow-up, 45 subjects (11%) had discontinued consumption of the capsules. Discontinuation was similar in both groups. Furthermore, 48 subjects (23 in the placebo group and 25 in the c9,t11 CLA group) had missing 6-mo follow-up PWV measurements. Finally, 346 subjects were included in the analyses, 173 in the control group and 173 in the c9,t11 CLA group (Figure 1) . The mean compliance rate was 93% in the placebo group and 92% in the c9,t11 CLA group. Both arms had similar mean (6SE) follow-up times between baseline and postbaseline PWV measurements (control group: 179 6 2 d; c9,t11 CLA group: 180 6 2 d). Demographic characteristics and CVD risk markers at baseline were similar between the 2 groups ( Table 2) .
After 6 mo of supplementation, mean (6SE) PWV did not change in the c9,t11 CLA group compared with the placebo group (D0.00 6 0.07 compared with D0.09 6 0.06 m/s) ( Table 3) . Results did not differ when analyses were performed in accordance with the per-protocol principle (n = 172 in each group) among compliant subjects only (n = 146 in the placebo group and 141 in the c9,t11 CLA group) or after imputation of missing values (data not shown). We observed no interaction with sex, SCORE, degree of obesity, or pretest PWV. Pearson correlation coefficients between changes in PWV and changes in blood pressure, mean arterial pressure, pulse pressure, and central vascular measures varied from 0.05 to 0.26 in the c9,t11 CLA group and from 0.01 to 0.25 in the placebo group.
There were no significant differences in changes in mean systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure between the c9,t11 CLA and placebo groups; neither were there between-group differences in central aortic systolic and diastolic blood pressure or central aortic pulse pressure ( Table 3 ). The effects of 6 mo of supplementation on body weight, BMI, waist circumference, and waist-hip ratio did not differ significantly between the c9,t11 CLA and placebo groups. However, we observed an increase in all of these measures in the placebo group, and in waist circumference in the c9,t11 CLA group (Table 3) .
Plasma concentrations of triglycerides, total, LDL, and HDL cholesterol, and total/HDL cholesterol ratio did not change significantly in the c9,t11 CLA group compared with the placebo group. There were no significant between-group differences in changes in plasma glucose, insulin, HOMA-IR, or CRP (Table  3) . When individuals with CRP concentrations .10 mg/L were excluded, the findings for CRP did not change.
In total, 188 AEs were reported by 102 subjects of the c9,t11 CLA group and 170 AEs by 94 subjects in the placebo group, without a statistically significant difference (P = 0.59). Seven SAEs were reported in the c9,t11 CLA arm and 8 SAEs in the placebo group. All SAEs were judged to be unrelated to the use of c9,t11 CLA.
DISCUSSION
In this 6-mo, double-blind, randomized, placebo-controlled, parallel-group trial, we observed no significant effect of c9,t11 CLA supplementation on aortic PWV, blood pressure, plasma lipids, glucose, insulin resistance, body composition, or CRP in apparently healthy but overweight and obese adults. cis-9,trans-11 CLA AND AORTIC STIFFNESS
The strengths of our study include its large sample size and its double-blind, randomized, placebo-controlled design, which decreased the possibility of bias. However, some aspects of the study need to be addressed. First, we had no information on dietary intake at baseline and changes in diet during the intervention. Although we cannot exclude differences in baseline dietary intake between the 2 groups, we expect intake to be similar because of the large sample size and randomized design of our study. Furthermore, although participants were requested not to change dietary habits during the intervention period, we cannot exclude the possibility that between-group differences in dietary intake during the intervention may have influenced our results. This would be particularly relevant if the 2 interventions had been calorically different from each other. Because this is not the case, we assume that potential changes in dietary intake were equal in both groups. Second, in our study we focused on the effect of c9,t11 CLA by using an investigational product that consisted of 2.5 g c9,t11 CLA and 0.6 g t10,c12 CLA. Although the t10,c12 CLA content of the product was relatively low and probably too low for any of the effects to be attributed to it (15), we cannot exclude the possibility that our results may be partly attributable to this isomer as well.
This study is, to our knowledge, the first to investigate the effect of supplementation with a predominantly single isomer, c9,t11 CLA, on aortic PWV, and we observed no significant effect after 6 mo. Raff et al (21) reported that consumption of a CLA (mixture)-rich diet for 5 wk, which provided 4.7 g of c9,t11 CLA and t10,c12 CLA isomers in equal amounts per day, did not affect brachial endothelial function, as another early marker of atherosclerosis, in 60 young and healthy men, which agrees with our finding. However, Taylor et al (22) observed that endothelial function, assessed by brachial artery flow-mediated dilatation, worsened after 12 wk of supplementation with a mixture of 4.5 g CLA/d, comprising approximately equal proportions of c9,t11 CLA and t10,c12 CLA, in 40 middle-aged overweight and obese men. Potential explanations for this difference from our findings may be differences in proportion of CLA isomers provided [50:50 compared with 80:20 proportion of c9,t11 and t10,c12 CLA (9, 10)] and in study endpoints. Because endothelial dysfunction is a process that occurs very early on in the development of atherosclerosis (41) as compared with arterial stiffness, it might be that endothelial function has relation with our intervention.
Several reasons for no detection of a statistically significant effect of c9,t11 CLA on PWV need to be considered before we can exclude an effect from this study. First, the power is mainly driven by the anticipated treatment effect and by the rate of change. The power calculation for our study was based on the 2 For differences between the c9,t11 CLA and control group, P values were obtained by using a 2-sided t test for means 6 SEs and a chi-square test for n (%).
3 Mean 6 SE (all such values). 4 Mean; 95% CI in parentheses (all such values). 5 Significant within-group change from baseline, P , 0.05 (paired t test). 6-9 For placebo and c9,t11 CLA groups, respectively:
6 n = 170 and n = 172, 7 n = 167 and n = 170, 8 n = 168 and n = 170, 9 n = 166 and n = 166.
effects of statin use for 6 mo to 1 y on PWV (36) (37) (38) (39) , which suggests that we would be able to detect an 8% difference between 2 groups of 180 subjects each. However, the effect produced by CLA supplementation was more subtle and maybe more in line with what could be expected from a food supplement. However, the observed change in aortic PWV in the placebo group in a 6-mo period was comparable to that which has been reported elsewhere (36) (37) (38) (39) or which could be extrapolated from cross-sectional studies that looked into aging effects (27, 42) . To evaluate an observed 1.2% difference between the groups, 1264 subjects per group would have been needed. This clearly reflects the fact that CLA is unlikely to affect PWV. Unfortunately, no comparable studies that investigated the effect of nutritional intervention on PWV have been performed so far. Second, the dose of CLA provided in our study (2.5 g c9,t11 CLA) may have been too low to induce significant effects. The antiatherogenic effects of c9,t11 CLA in animal studies were based on dietary doses that ranged from 0.5% to 2.1% of energy (9, 10, (43) (44) (45) (46) (47) , which would be equivalent to supplementation doses of 1.4-5.8 g CLA in humans (based on a daily intake of 2500 kcal). Third, it is unlikely that our results are influenced by subjects who discontinued taking study capsules (1%) or by dropouts caused by missing follow-up PWV values (12%), because analyses carried out in accordance with the per-protocol principle and with imputed values for missing PWV values revealed similar results. Attenuation of observed effects due to noncompliance (10%) is not likely because analyses restricted to compliant subjects showed results comparable to the intention-to-treat analyses. Fourth, although our study included overweight and obese participants, the absence of an effect may also be attributed to our participants being generally healthy, with relatively few smokers, and with normal plasma lipid and glucose concentrations. Animal studies that reported effects of CLA on atherosclerosis were mainly performed in animals models prone to atherosclerosis development (8) .
It is important to note that changes in PWV may be (partly) a result of changes in its determinants, such as blood pressure and body weight. We observed no effect of c9,t11 CLA on these determinants, which may also explain the lack of a statistically significant effect on aortic PWV. Others have also reported no effect of a CLA mixture on systolic and diastolic blood pressure (21, 48) . It is known that aortic PWV and atherosclerosis can be affected via other pathways, such as inflammation (49) , which indicates that c9,t11 CLA may still have an effect on atherosclerosis through this pathway. However, we did not find an effect of c9,t11 CLA on CRP. Other human trials have not observed an effect of 1.4-5.1 g c9,t11 CLA/d (14, 16, 18) .
Thus far, most human intervention studies have suggested little evidence for an effect of c9,t11 CLA on CVD risk markers, such as plasma lipid concentrations, body composition, and insulin resistance (8, 11-16, 20, 50) , although one study, which included 25 abdominally obese men, observed a decrease in insulin sensitivity after 3 mo of supplementation with 3.2 g c9,t11 CLA/d (13) . However, studies performed thus far have been relatively small in number (25-90 subjects), with large variations in study duration (3-18 wk), intervention doses of c9,t11 CLA (0.6-5.5 g/d), types of placebo, and subject characteristics such as sex, age, and BMI range. Our study, with a substantially larger study population of persons who were either overweight or obese, and with a relatively long study duration, however, confirmed the neutral effects of c9,t11 CLA on blood lipid concentrations, body composition, and insulin resistance.
CLA can be considered a ruminant-derived trans fatty acid. Observational studies suggested no association between CVD risk and ruminant trans fatty acids but increased risk with industrial trans fatty acids (4). However, 2 recent dietary-controlled trials that compared ruminant and industrial trans fatty acids reported deterioration of blood lipids with high doses (3.6-5.0% of energy) of both trans fatty acid sources (5, 6) but not with a moderate dose (1.5% of energy) of ruminant trans fatty acids (6) , which suggests that dose is more important than source. Although we did not address industrial trans fatty acids, our study supports the lack of effect on CVD risk markers with relatively low doses of ruminant trans fatty acids.
The dose administered, 2.5 g c9,t11 CLA/d and 0.6 g t10,c12 CLA/d, might be considered a safe dose with regard to CVD risk. CLA concentrations in ruminant meat and milk are ,1% of total fat (51) . Consequently, human CLA intake is quite low [212 mg/d in men and 151 mg/d in women (52)], and it would be difficult to achieve CLA intakes comparable to the dose investigated in this study. However, an alteration in ruminant feeding could be used to increase CLA intakes (53) . Nevertheless, because we observed no effects on PWV or other CVD risk markers, our study does not provide evidence for a role of c9,t11 CLA in CVD risk reduction.
In conclusion, this study does not support an antiatherosclerotic effect or an effect on other CVD risk markers of c9,t11 CLA in overweight and obese adults.
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